Evidence map›Paper›PMID 20813124›Full record

ArticleMechanisms of ageing and development2010

High-affinity Na(+)-dependent dicarboxylate cotransporter promotes cellular senescence by inhibiting SIRT1.

Weiping Liu, Quan Hong, Xue-Yuan Bai, Bo Fu, Yuansheng Xie, Xueguang Zhang, Jianjun Li, Suozhu Shi, Yang Lv, Xuefeng Sun and 1 more

Open access · greenAbstract read
In one paragraph

Article in Mechanisms of ageing and development, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family.Pflugers Archiv : European journal of physiology · 2014
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Weiping LiuDepartment of Nephrology, Chinese PLA Institute of Nephrology & Key Lab, Chinese PLA General Hospital, Beijing, PR China.
Quan Hong
Xue-Yuan Bai
Bo Fu
Yuansheng Xie
Xueguang Zhang
Jianjun Li
Suozhu Shi
Yang Lv
Xuefeng Sun
Xiangmei Chen
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-affinity Na(+)-dependent dicarboxylate cotransporter (NaDC3) can transport Krebs cycle intermediates into cells. Our previous study has shown that NaDC3 promotes cellular senescence, but its mechanism is not clear. It is known that when the concentration of intermediates in Krebs cycle is increased, NAD(+)/NADH ratio will be decreased. NAD(+)-dependent histone deacetylase sirtuin1 (SIRT1) prolongs mammalian cellular lifespan. Therefore, we propose that NaDC3 accelerates cellular aging by inhibiting SIRT1. After NaDC3 was overexpressed in two human embryo lung fibroblastic cell lines, WI38 and MRC-5, we found that the cells displayed aging-related phenotypes in advance. Meanwhile, the level of SIRT1 activity was down-regulated. In WI38/hNaDC3 cells treated with the activators of SIRT1, aging-related phenotypes induced by NaDC3 were obviously improved. The NAD(+)/NADH ratio in WI38/hNaDC3 cells was also decreased. Further study found that enhanced intracellular NAD(+) level could attenuate the aging phenotypes induced by NaDC3. Thus, NaDC3 promotes cellular senescence probably by inhibiting NAD(+)-dependent SIRT1.

Indexed as

AnimalsCell LineCellular SenescenceCitric Acid CycleHumansMaleNADOrganic Anion Transporters, Sodium-DependentRatsRats, WistarSirtuin 1NADOrganic Anion Transporters, Sodium-DependentSIRT1 protein, humanSirt1 protein, ratSirtuin 1

Identifiers

PMID20813124
PMCPMC7127227
OpenAlexW2080774650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.